Can Tranexamic Acid Stop a GI Bleed?
Tranexamic acid should NOT be routinely used for gastrointestinal bleeding, as it does not reduce mortality and may increase thromboembolic complications, particularly venous thromboembolism and seizures. 1, 2
Guideline Recommendations
The British Society of Gastroenterology (2019) explicitly recommends that tranexamic acid use in acute lower GI bleeding should be confined to clinical trials only, pending results from definitive studies 1. While older pooled analyses of upper GI bleeding trials showed a 40% mortality reduction, this benefit disappeared when limited to high-quality, low-risk-of-bias studies 1. These historical trials preceded modern endoscopic therapy and high-dose proton pump inhibitor use, making their applicability to current practice uncertain 1.
Definitive Evidence from the HALT-IT Trial
The HALT-IT trial (2020), the largest and highest-quality study with 12,009 patients, definitively demonstrated that high-dose extended tranexamic acid (1g loading dose followed by 3g over 24 hours) does NOT reduce death from bleeding (4% vs 4%; RR 0.99,95% CI 0.82-1.18) 2. Critically, this trial revealed significant safety concerns:
- Increased venous thromboembolism: Deep vein thrombosis or pulmonary embolism occurred in 0.8% with TXA versus 0.4% with placebo (RR 1.85,95% CI 1.15-2.98) 2
- No difference in arterial thromboembolism (myocardial infarction or stroke): 0.7% vs 0.8% 2
Meta-Analysis Evidence Shows Mixed Results
Recent systematic reviews (2022-2025) confirm the HALT-IT findings for high-dose IV tranexamic acid:
- No mortality benefit: Extended-use high-dose IV TXA does not reduce mortality (RR 0.98,95% CI 0.88-1.09) with high certainty 3
- Increased adverse events: Significant increases in deep venous thrombosis (RR 2.01,95% CI 1.08-3.72), pulmonary embolism (RR 1.78,95% CI 1.06-3.0), and seizures (RR 1.73,95% CI 1.03-2.93) 3
- No reduction in bleeding: High-dose TXA does not reduce bleeding (RR 0.92,95% CI 0.82-1.04) 3
Important Distinction: Upper vs Lower GI Bleeding
The evidence differs significantly by bleeding source:
- Upper GI bleeding: Some meta-analyses suggest TXA may reduce rebleeding rates (RR 0.64,95% CI 0.45-0.91) and need for surgery (RR 0.58,95% CI 0.38-0.88) with low-dose regimens 4, 5, 3
- Lower GI bleeding: One large analysis showed increased mortality with TXA (RR 1.67,95% CI 1.44-1.93) 6
Special Population: Cirrhosis with Variceal Bleeding
A 2024 RCT in 600 patients with Child-Pugh B/C cirrhosis showed TXA reduced 5-day treatment failure (6.3% vs 13.3%, p=0.006), particularly from post-EVL site bleeding (4.9% vs 12.0%, p=0.005), though 5-day and 6-week mortality remained unchanged 7. This represents a specific exception where TXA may have benefit in preventing post-endoscopic variceal ligation bleeding.
FDA Labeling
The FDA-approved indication for tranexamic acid is limited to patients with hemophilia undergoing tooth extraction (10 mg/kg IV 3-4 times daily for 2-8 days) 8. The label explicitly warns about thromboembolic risks and notes the drug should be infused no faster than 1 mL/minute to avoid hypotension 8. There is no FDA approval for gastrointestinal bleeding 8.
Clinical Bottom Line
Do not use tranexamic acid for acute gastrointestinal bleeding in routine practice 1, 2, 9. The highest-quality evidence shows no mortality benefit, no reduction in bleeding, and increased risk of venous thromboembolism and seizures 2, 3. The only potential exception is in patients with advanced cirrhosis and variceal bleeding to prevent post-EVL site bleeding, though this requires further validation 7. Standard management should focus on resuscitation, endoscopic therapy, proton pump inhibitors for upper GI bleeding, and interventional radiology when indicated 1, 10.